Knight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Sells 300,000 Shares of Stock

Knight Therapeutics Inc. (TSE:GUD) insider Sime Armoyan sold 300,000 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of C$6.13, for a total transaction of C$1,839,000.00.

Knight Therapeutics Price Performance

Shares of GUD stock opened at C$6.02 on Friday. Knight Therapeutics Inc. has a 1 year low of C$4.35 and a 1 year high of C$6.23. The company has a current ratio of 3.41, a quick ratio of 1.79 and a debt-to-equity ratio of 7.62. The firm’s 50 day moving average is C$5.72 and its 200-day moving average is C$5.69. The firm has a market capitalization of C$609.28 million, a price-to-earnings ratio of -30.10, a PEG ratio of -1,013.50 and a beta of 0.48.

Knight Therapeutics (TSE:GUD) last posted its quarterly earnings data on Thursday, August 8th. The company reported C($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.03 by C($0.05). The firm had revenue of C$95.57 million for the quarter, compared to analyst estimates of C$89.83 million. Knight Therapeutics had a negative return on equity of 2.70% and a negative net margin of 6.28%. Sell-side analysts forecast that Knight Therapeutics Inc. will post 0.1077501 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on GUD. Stifel Canada upgraded shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 12th. Stifel Nicolaus raised Knight Therapeutics from a “hold” rating to a “buy” rating and boosted their target price for the stock from C$5.75 to C$6.75 in a report on Tuesday, August 13th.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.